Drugs that contain Naldemedine Tosylate
1. Symproic patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46375 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Oct, 2026
(2 years from now) | |
| US8536192 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Oct, 2026
(2 years from now) | |
| USRE46365 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Jan, 2028
(3 years from now) | |
| US8084460 | BDSI | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative |
Jan, 2028
(3 years from now) | |
| US9108975 | BDSI | Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same |
Nov, 2031
(7 years from now) | |
| US10952968 | BDSI | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 23, 2022 |
NCE-1 date: 23 March, 2021
Market Authorisation Date: 23 March, 2017
Treatment: Treatment of opioid-induced constipation
Dosage: TABLET;ORAL
More Information on Dosage
SYMPROIC family patents
